Sanofi and Regeneron to Initiate the Clinical Program Evaluating Kevzara (sarilumab) in Patients with Severe COVID-19

 Sanofi and Regeneron to Initiate the Clinical Program Evaluating Kevzara (sarilumab) in Patients with Severe COVID-19

Sanofi and Regeneron to Initiate the Clinical Program Evaluating Kevzara (sarilumab) in Patients with Severe COVID-19

Shots:

  • The P-II/III study will assess the safety & efficacy Kevzara + supportive care vs PBO + supportive care in ~400 patients in a ratio (2:2:1) hospitalized with serious complications from COVID-19
  • The study is designed into two parts:  First part will evaluate the impact of Kevzara on fever and patients’ need for supplemental oxygen while the second part will evaluate the improvement in longer-term outcomes including preventing death & reducing the need for mechanical ventilation, supplemental oxygen and/or hospitalization
  • Kevzara is a mAb inhibiting IL-6 pathway by targeting the IL-6 receptor. The companies will continue to collaborate on COVID-19 and other ARDS development, with Regeneron leading US studies and Sanofi leading ex-US studies. In 2019, the companies intend to simplify the joint collaboration for Kevzara, which is expected to be finalized in the Q1’20

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: Pharmaceutical Technolog

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post